A study published Wednesday in JAMA Psychiatry presents evidence that psychedelics may have therapeutic potential for treating conditions marked by inflammation and immune system dysregulation. The research, conducted by scientists at the University of California, San Francisco, examined blood samples from participants with Parkinson’s disease before and after receiving psilocybin in two sessions.
The analysis measured five signaling molecules related to inflammation, along with a blood marker indicating mitochondrial stress. Participants demonstrated significantly reduced inflammation levels following treatment compared to their baseline measurements, with these improvements persisting one month after their final psilocybin dose. Blood markers of mitochondrial stress showed substantial improvements immediately after administration, though long-term follow-up data proved less conclusive.
The findings originated from a pilot study involving 12 participants designed to assess the feasibility and safety of administering psilocybin to people with Parkinson’s disease. The original study, published the previous year, had determined a favorable safety profile. Researchers acknowledge important study limitations, including the absence of a control group and participants’ awareness of receiving the drug. Dr. Aoife O’Donovan, a co-author and professor of psychiatry and behavioral sciences at UCSF, emphasized that objective markers changed measurably over time, warranting further investigation.
Parkinson’s disease involves dysregulated inflammation and mitochondrial dysfunction, potentially explaining the observed benefits. The research suggests psychedelics could address other inflammatory conditions beyond neurodegeneration. Previous investigations of psychedelic anti-inflammatory effects have primarily involved healthy volunteers rather than patients with active disease. Experts note the findings validate 15 years of laboratory research demonstrating that certain psychedelics can produce powerful anti-inflammatory effects, marking an important transition toward human clinical validation of these mechanisms.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI